Genetic Biomarkers of Cognitive Impairment and Dementia of Potential Interest in CKD Patients

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2024 Jul 6

PMID 38970746

Authors

Carmine Zoccali

Giovambattista Capasso

Affiliations

Soon will be listed here.

Abstract

This review discusses genetic variants associated with cognitive dysfunction in chronic kidney disease (CKD) patients, emphasising the limited research in this area. Four studies have explored genetic markers of cognitive dysfunction in CKD, with findings suggesting shared genetic biomarkers between Alzheimer's Disease and CKD.Because of the limited specific research on genetic markers of cognitive dysfunction and dementia in CKD, we extracted data from the current literature studies on genetic markers in the general population that may be relevant to the CKD population. These markers include Apolipoprotein E (APOE), Complement Receptor 1 (CR1), Clusterin (CLU), Sortilin-related receptor 1 (SORL1), Catechol-O-methyltransferase (COMT), and Brain-derived neurotrophic factor (BDNF), all of which are known to be associated with cognitive dysfunction and dementia in other populations. These genes play various roles in lipid metabolism, inflammation, Aβ clearance, and neuronal function, making them potential candidates for studying cognitive decline in CKD patients.CKD-specific research is needed to understand the role of these genetic markers in CKD-related cognitive dysfunction. Investigating how these genes influence cognitive decline in CKD patients could provide valuable insights into early detection, targeted interventions, and personalised treatment strategies. Overall, genetic studies to enhance our understanding and management of cognitive dysfunction in CKD represent a clinical research priority in this population.

Citing Articles

Health outcomes in chronic kidney disease patients with cognitive impairment or dementia: a global collaborative analysis.

Merlino L, Rainone F, Chinnadurai R, Hernandez G, Tollitt J, Battini G Clin Kidney J. 2025; 18(1):sfae401.

PMID: 39866298 PMC: 11761004. DOI: 10.1093/ckj/sfae401.

References

Kalantar-Zadeh K, Jafar T, Nitsch D, Neuen B, Perkovic V . Chronic kidney disease. Lancet. 2021; 398(10302):786-802. DOI: 10.1016/S0140-6736(21)00519-5. View

Levey A, Coresh J . Chronic kidney disease. Lancet. 2011; 379(9811):165-80. DOI: 10.1016/S0140-6736(11)60178-5. View

Madero M, Gul A, Sarnak M . Cognitive function in chronic kidney disease. Semin Dial. 2008; 21(1):29-37. DOI: 10.1111/j.1525-139X.2007.00384.x. View

Aliberti M, Cenzer I, Smith A, Lee S, Yaffe K, Covinsky K . Assessing Risk for Adverse Outcomes in Older Adults: The Need to Include Both Physical Frailty and Cognition. J Am Geriatr Soc. 2018; 67(3):477-483. PMC: 6510389. DOI: 10.1111/jgs.15683. View

Wang M, Li T, Li C, Liu C, Lin C, Lin W . Cognitive function and its transitions in predicting all-cause mortality among urban community-dwelling older adults. BMC Psychiatry. 2020; 20(1):203. PMC: 7201694. DOI: 10.1186/s12888-020-02618-9. View

Toyoda K, Ninomiya T . Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014; 13(8):823-33. DOI: 10.1016/S1474-4422(14)70026-2. View

Kim D, Grodstein F, Newman A, Chaves P, Odden M, Klein R . Microvascular and Macrovascular Abnormalities and Cognitive and Physical Function in Older Adults: Cardiovascular Health Study. J Am Geriatr Soc. 2015; 63(9):1886-93. PMC: 4578971. DOI: 10.1111/jgs.13594. View

Bugnicourt J, Godefroy O, Chillon J, Choukroun G, Massy Z . Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol. 2013; 24(3):353-63. DOI: 10.1681/ASN.2012050536. View

Li J, Li Y, Niu J, Zhang J, Cheng X . Exploration of the shared genetic biomarkers in Alzheimer's disease and chronic kidney disease using integrated bioinformatics analysis. Medicine (Baltimore). 2023; 102(44):e35555. PMC: 10627605. DOI: 10.1097/MD.0000000000035555. View

10.

Liu X, Ou Y, Ma Y, Huang L, Zhang W, Tan L . Renal function and neurodegenerative diseases : a two-sample Mendelian randomization study. Neurol Res. 2023; 45(5):456-464. DOI: 10.1080/01616412.2022.2158640. View

11.

Marini S, Georgakis M, Chung J, Henry J, Dichgans M, Rosand J . Genetic overlap and causal inferences between kidney function and cerebrovascular disease. Neurology. 2020; 94(24):e2581-e2591. PMC: 7455337. DOI: 10.1212/WNL.0000000000009642. View

12.

Liu C, Liu C, Kanekiyo T, Xu H, Bu G . Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9(2):106-18. PMC: 3726719. DOI: 10.1038/nrneurol.2012.263. View

13.

Chu A, Parekh R, Astor B, Coresh J, Berthier-Schaad Y, Smith M . Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study. BMC Med Genet. 2009; 10:108. PMC: 2770999. DOI: 10.1186/1471-2350-10-108. View

14.

Corder E, Saunders A, Risch N, Strittmatter W, Schmechel D, Gaskell Jr P . Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994; 7(2):180-4. DOI: 10.1038/ng0694-180. View

15.

Rebeck G, Kindy M, LaDu M . Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis. 2002; 4(3):145-54. DOI: 10.3233/jad-2002-4304. View

16.

Mahley R, Weisgraber K, Innerarity T, Rall Jr S . Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA. 1991; 265(1):78-83. DOI: 10.1001/jama.265.1.78. View

17.

Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261(5123):921-3. DOI: 10.1126/science.8346443. View

18.

Ernandez T, Mayadas T . The Changing Landscape of Renal Inflammation. Trends Mol Med. 2016; 22(2):151-163. PMC: 4738004. DOI: 10.1016/j.molmed.2015.12.002. View

19.

Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J . Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology. 2011; 217(2):244-50. DOI: 10.1016/j.imbio.2011.07.017. View

20.

Lambert J, Heath S, Even G, Campion D, Sleegers K, Hiltunen M . Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009; 41(10):1094-9. DOI: 10.1038/ng.439. View